Sirolimus
Neurofibromatosis
The University of Texas Health Science Center, HoustonSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Neurofibromatosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Dexmedetomidine Medical College of Wisconsin | Phase 4 | BB |
Lidocaine Medical College of Wisconsin | Phase 4 | BB |
Glycopyrrolate Medical College of Wisconsin | Phase 4 | BB |
Dinitrogen Monoxide Medical College of Wisconsin | Phase 4 | BB |
Propofol Medical College of Wisconsin | Phase 4 | BB |
Sevoflurane Medical College of Wisconsin | Phase 4 | BB |
Same molecule, other indications
Sirolimus is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →